Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



MAR 29, 2013 - Yahoo! News

A Must Read - Share

Biogen prices new MS drug at discount to key competitors

WASHINGTON (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," said Kate Niazi-Sai, a Biogen spokeswoman. ...

Tags: Biogen prices new MS drug at discount to key competitors,  Multiple Sclerosis Latest News